Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
Actively Recruiting
Researchers are conducting a randomized, double-blind, sham-controlled clinical trial to compare the immediate effects of two types of photobiomodulation PBM therapies on blood pressure, endothelial function, and arterial stiffness in people with hypertension. The study includes participants aged 40 to 60 years who have been diagnosed with hypertension for at least 3 months and are using blood pressure medications. The goal is to better understand how these light-based therapies may influence cardiovascular measures in this population. Participants will be randomly assigned to one of four groups full-body PBM from an LED panel, sham panel treatment with the device turned off, modified intravascular laser irradiation of blood ILIB therapy, or sham ILIB treatment with the device turned off. Each participant will receive a single application of the assigned therapy. The LED panel uses a wavelength of 660 nm with specific energy and power settings, while the modified ILIB also uses 660 nm but with different energy and power characteristics. Before and after the intervention, participants will be assessed for blood pressure, endothelial function, arterial stiffness, blood nitrite levels, and skin thermography. Ambulatory blood pressure monitoring will be performed after the intervention to track blood pressure over 24 hours. The primary outcome is the diastolic blood pressure effect immediately and up to 24 hours post-treatment. Secondary outcomes include systolic and mean arterial pressure, endothelial function, arterial stiffness, and blood nitrite changes measured at specified times after the therapy. Data analysis will determine if the therapies have significant acute effects on these cardiovascular parameters.
Actively Recruiting
Researchers are evaluating whether cognitive functional therapy is more effective than therapeutic exercises in reducing pain and disability for individuals with chronic shoulder pain. This randomized controlled trial includes 148 participants aged 18 to 65 years who have experienced shoulder pain for at least three months. The study aims to understand which treatment better improves pain, disability, function, and psychosocial factors related to shoulder pain. Participants will be randomly assigned to one of two groups. One group will receive cognitive functional therapy once a week for four to eight weeks, focusing on changing beliefs about pain, gradually exposing patients to movements, and promoting lifestyle changes. The other group will follow a therapeutic exercise program twice a week for eight weeks, targeting shoulder muscles with specific exercises using progressive resistance bands. Throughout the study, participants will undergo assessments at baseline, four weeks, eight weeks, and a 12-week follow-up. Researchers will measure pain intensity, shoulder disability, specific function, fear of movement, pain self-efficacy, sleep quality, treatment expectations, perception of change, treatment satisfaction, and exercise adherence. The study includes monitoring for safety, and participants may be discontinued if certain injuries or treatments occur during the trial.
Actively Recruiting
Healthy Volunteer
Children with spastic cerebral palsy CP, a condition that affects movement and coordination, often struggle with daily activities such as dressing, reaching for objects, and standing up. These difficulties can reduce their quality of life. Researchers are studying the effects of a new treatment called the INTERACT protocol, which combines task-specific training with augmented reality AR games to improve upper limb function and daily activities in children with CP aged 6 to 12 years. The study will randomly assign children to two groups the INTERACT group and a control group. The INTERACT group will participate in training sessions using AR games that encourage movements like reaching, sitting to standing, and stepping. These sessions will last 1 hour and 20 minutes, three times a week, for 4 weeks. The control group will continue their usual physiotherapy during the same period. The AR games use special software and equipment to track movements and create interactive, motivating exercises. Participants will be evaluated before the intervention, immediately after, and two months later to measure improvements. Assessments include movement analysis, disability scales, postural control tests, and questionnaires about daily activities and motivation. Throughout the study, therapists will monitor progress and adherence. This research aims to provide new evidence on how combining task training with AR can support motor learning and improve life skills in children with spastic CP.
Actively Recruiting
Healthy Volunteer
Researchers are studying how light reflects off human skin during whole-body photobiomodulation therapy PBMT, which uses low-intensity red and infrared light to affect biological tissues. The trial focuses on men and women aged 18 to 30 years and aims to understand how different skin phototypes influence light reflection when the therapy is applied without skin contact. This research is led by Universidade Federal de Sao Carlos. Participants will receive whole-body photobiomodulation therapy using a device that emits red light 660 nm and infrared light 850 nm for a total of about 10 minutes5 minutes for each wavelength. The light source will be held 20 cm from the skin during treatment. Participants will be grouped by skin phototype using the Fitzpatrick scale to compare light reflection across skin types. The reflection will be measured in multiple body areas including the brachial biceps, abdomen, lumbar region, front and back of the thighs, and calves. During the therapy session, light reflection will be measured using specialized sensors and a powermeter. This measurement will occur only during the light therapy irradiation on the day of the procedure. Researchers will analyze reflection data to see how skin type affects light interaction with the skin. The study involves healthy volunteers with normal to overweight BMI, and participation is expected to last for the duration of the single treatment session.
Actively Recruiting
Researchers are investigating ways to identify people in Brasil who may have undiagnosed chronic respiratory diseases CRDs like asthma and chronic obstructive pulmonary disease COPD. This study focuses on adults who already have other long-term health conditions such as heart disease, diabetes, or high blood pressure and attend primary health care centers in the cities of Sao Carlos and Sao Paulo. The goal is to evaluate simple questionnaires that can help detect these lung conditions early in people with other health problems. Participants will complete two questionnaires called COLA-6 and the Symptom-Based Questionnaire SBQ, which are quick and easy to use. Each person will also undergo lung function tests including spirometry before and after using a bronchodilator, as well as a fractional exhaled nitric oxide FeNO test to confirm lung health. Additional questionnaires related to asthma and chronic airway symptoms will be given to those with abnormal lung tests. The study will classify participants based on lung test results following recognized guidelines to identify different types of lung issues. All assessments are done during a single visit with a research team member. Participants will provide consent and undergo initial evaluations, questionnaires, and lung tests. The study will analyze how well the questionnaires identify abnormal lung function compared to spirometry results. Researchers will also collect information about participants health and lung conditions to better understand lung disease detection in people with other chronic illnesses. The study plans to recruit 859 individuals and will be completed by mid-2027.
1-10 of 12
1